4D Molecular Therapeutics:
4D Molecular Therapeutics’ mission is to design and develop transformative gene therapy products to treat conditions with serious unmet medical need using our proprietary “directed evolution” platform for the creation of adeno-associated virus variants.
Achelois Pharamceuticals Inc.
Achelois’ mission is to develop effective and nontoxic therapeutics to inhibit tumors, and to eliminate pain and suffering caused by cancer.
Convoy Therapeutics and EnduRx Pharmaceuticals (subsidiaries of ACTUS Biotechnologies)
Origin: Tucson AZ and San Diego, CA | Leadership: John Muraski, President
Focus: Therapeutics and Aesthetics
Convoy’s technology platform focuses on solving major unmet needs in aesthetics and pharmaceutical markets by creating novel topical products that are more effective, safer and easier to use; EnduRx is developing therapeutics that specifically target diseased tissue, with the front-line program being focused on the development of a targeted nanosystem for the treatment of Glioblastoma Multiforme (GBM).
Aetheria Therapeutics is a privately-held pharmaceutical company that is dedicated to the discovery and development of novel, oral treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
Alector is dedicated to the discovery and development of novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. http://www.alector.com
Amydis Diagnostics, Inc.
Our mission is to be the leader in detecting/monitoring Alzheimer’s disease. We are dedicated to improving the lives of patients by significantly improving the accessibility, effectiveness and ease of testing for Alzheimer’s.
Arcturus Therapeutics, Inc:
Origin: San Diego, CA | Leadership: Joseph E. Payne, Founder and CEO; Pad Chivukula, Founder and CSO
Arcturus is poised to become an industry leader in RNAi technologies for the treatment of rare orphan diseases.
Biologics are protein-based antibody drugs used to treat cancers, autoimmune disorders, and other chronic diseases. Comprised of very large molecules and typically delivered intravenously in high concentrations over several hours, these therapeutics are usually administered in hospitals settings or infusion clinics. Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Arsia’s proprietary technology to make injectable formulations of high-concentration antibody drugs can be applied to existing branded biologics, biosimilars, as well as biologics in development.
Origin: Bloomington, Indiana and San Francisco, CA |Leadership: Founders: Uri Lopatin, CMO; Adam Zlotnick, CSO; William Turner, Head of Chemistry; Derek Small, Executive Chair; Richard Dimarchi, Director
Focus: Small Molecule Antivirals
Curative therapy for Hepatitis B
Avidity NanoMedicines LLC
Origin: Pasadena, CA | Leadership: Troy Wilson, President & CEO; P. Kent Hawryluk, Chief Business Officer
Development of targeted nanoparticle medicines for the treatment of cancer and other serious diseases.
Batu Biologics is an immunotherapy company dedicated to developing therapeutics that address the multi-factorial and multi-dimensional nature of cancer. Our company believes that a major failure of the conventional approach to oncology is attributed to the overspecialized focus on singular biological pathways, without understanding the “greater picture” of tumor biology. Cancer progression is a dynamic biologic process; tumors possess the ability to escape therapeutic interventions by mutating the targets of the intervention. In the case of chemotherapy, tumors develop resistance by mutating genes to make the cells less susceptible to chemotherapy. In the case of immune therapy, tumor cells lose expression of the protein markers (antigens) that the immune therapy is targeting. This can be seen by the recent failure of GSK’s Phase III cancer vaccine targeting a single tumor protein, MAGE.
Breakthrough Genetics aims to transform cancer diagnostics with point-of-care tests to target oncogenic mutations.
Origin: San Diego, CA | Leadership: Jeff Stein, President & CEO, Kevin Forrest Co-Founder and COO; Kevin Judice Co-Founder and CSO; Dirk Thye CMO; Ken Bartizal, Chief Development Officer
Cidara Therapeutics is applying its small molecule immunotherapy platform to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Our initial focus is on devastating fungal infections that often complicate cancer and transplant treatments
Clinical Metabolics (Clinmet)
ClinMet uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Our unique combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Our efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug's mechanism of action.
Cognuse Inc. is a leading cognitive rehabilitation platform provider helping hospitals and rehabilitation clinics better assess and treat patients with neurological conditions such as strokes, TBI, ADHD, Alzheimer’s, MCI and Multiple Sclerosis. Cognuse platform hosts a number of virtual exercises that are strongly related to real life themes by focusing on restoring and improving executive functions of the brain.
Antibody therapeutics for the immune synapse.
Cyteir Therapeutics, Inc.
Cyteir is revolutionizing the concept of DNA damage and repair. Conventional therapies focus on reversal of cancer cell properties and DNA damage to restore the normal state. Cyteir takes a contrarian approach by enhancing – not reducing – DNA damage to achieve rapid and selective elimination of only the diseased cells. On this basis Cyteir has developed and is now leveraging an integrated drug development platform to deliver a pipeline of small molecule therapeutics with a broad range of potential disease state applications..
Origin: Carlsbad, CA | Leadership: John F. Steel, CEO
Diagnostics, forensics, integrated DNA analysis and genetic solutions
DNAtrix is a privately held biotech company focusing on the development of oncolytic viruses for cancer. The company’s initial focus is on glioblastoma, a devastating brain tumor that is currently incurable. Since viruses are already good at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and kills cancer cells selectively. More than 35 patients have been treated with the cancer-killing virus, called DNX-2401, with excellent early results. Company’s lead product, DNX-2401, is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date. DNAtrix is also working to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company has offices located in Houston, Texas and San Diego, California.
Precision microbiome engineering company addressing problematic bacteria in agriculture and beyond. http://www.epibiome.com
Origin: Ann Arbor, MI | Leadership: Thomas Everist, Chairman
Focus: Personalized Medicine and Diagnostics
Develops and commercializes medically unique molecular and sensor based diagnostics, prognostics and therapeutic selection technologies for cancer and cardiovascular diseases, which help physicians improve medical outcomes and reduce the total cost of care.
Glycosensors & Diagnostics
Glycosensors & Diagnostics, LLC (G&D) is commercializing enabling technologies for applications in glycan analysis. G&D’s Lectenz® and GlycoSenseTM platforms enable glycan identification and analysis for applications in disease biomarker detection and bioprocessing of biologics and biosimilars. G&D’s products offer a robust, cost-effective, and unique solution (patents pending) to current bottlenecks in glycan analysis and will simplify the workflow associated with glycoprofiling during biologics development, biomanufacturing, diagnostics, and R&D.
Early stage R&D of bispecific antibodies for the treatment of hematological malignancies and solid tumors.
Using a novel new medicinal chemistry platform, HTI is focused on the development and commercialization of direct acting antivirals for infections with the human papilloma virus, human and animal retroviruses and herpes group viruses.
Iconic Therapeutics, Inc.
Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Our deep understanding of the role of Tissue Factor (TF) in angiogenesis, inflammation, and metastasis has led us to develop a new approach to retinal disease and cancer. http://www.iconictherapeutics.com
Lµbris BioPharma is a development-stage life science company producing and commercializing a recombinant version of the human protein, lubricin. Lubricin is expressed in numerous parts of the human body and plays an important role in protecting surfaces from damage and wear.
Key opinion leaders and clinicians worldwide are focusing their research efforts on using lubricin to improve the lives of millions of people with a host of unmet medical needs including dry eye, osteoarthritis, surgical adhesions, xerostomia and pericarditis.
Early in 2015, it is anticipated that the first human clinical trial of a product containing lubricin will be commenced in Europe for the treatment of dry eye disease.
Advancing human longevity. http://www.metalaboratories.com
Origin: San Diego, CA/ Montreal, QC (Canada) |Leadership: Charles Baum, President and CEO
Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with a spectrum of complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team
Thirty years ago Bill Efcavitch PhD, and Curt Becker, as founding members of Applied Biosystems, developed and the first practical process for synthesizing DNA; the first step in creating the genomics industry. While enabling at the time, that $1B+ chemically based process is limited and is now an impediment for modern applications. Curt and Bill have reunited to solve this problem by developing a next generation enzymatic approach - transforming the concept from synthesizing DNA to writing genetic code and enabling a new era in biotechnology.
NAT Diagnostics, Inc. is an early stage company developing a rapid molecular diagnostic test that is suitable for use at the Point-of-Care. The core technology is based on a novel isothermal nucleic acid amplification and detection method that requires only five minutes.
A powerful therapeutic approach targeting the central regulator of nutrient signaling, cellular metabolism and growth.
New scientific insights are emerging regarding the primal signaling pathways that direct an organism’s metabolic response to conditions in its environment—such as dynamic changes in the availability of nutrients, energy, oxygen and other factors—and the role of these metabolic signaling pathways in disease. Navitor’s drug discovery platform leverages proprietary intellectual property and know-how related to key targets within nutrient signaling pathways and their fundamental role in disease processes. Our proprietary approach targeting nutrient signaling offers an entirely new treatment approach for a broad range of chronic and rare diseases.
Neurolixis Inc. is an early-stage biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system disorders including Parkinson's disease, Rett syndrome, depression and schizophrenia.
Origin: San Diego, CA | Leadership: Brian Spencer, Co-Founder & Chief Scientist; Mike Dunn, Co-Founder & CEO
NeuroTransit uses proprietary technology for the development of drug products that cross the blood-brain barrier (BBB) to treat neurologic, metabolic and oncologic diseases of the brain.
Nirmidas Biotech, Inc.
Origin: Stanford, CA | Leadership: Meijie Tang, CEO/Co-founder; Hongjie Dai, scientific founder
Focus: Biotechnology and Diagnostics
R&D and commercialization of high sensitivity detection platforms of biological systems for applications in the life science research, clinical research, and in vitro diagnostics.
Nucleo Life Sciences
Nucleo Life Sciences is a pharmaceutical company focused on developing novel therapeutics into commercially viable products through proven pharmaceutical development expertise and creative problem solving. http://www.nucleolifesciences.com/
Origin: San Francisco, CA | Leadership: Bob Messerschmidt, Founder and CEO
Focus: Med Device, In Vitro Diagnostics
Nueon technology will provide integrated, risk-related hypertension measurement. We use optical technology to measure red blood cell membrane chemistry, in whole blood from a fingerstick, in less than a minute in the point of care.
PHusis is designing precision medicines using its proprietary computational modeling platform, PHuDock to rapidly identify inhibitors of proteins with regulatory PH-domains that drive cancer growth. The approach provides PHusis with the means of identifying drug leads more rapidly and in a cost effective manner. The result is, PHusis has built a pipeline of drug leads against some novel and critical cancer targets including PDK1, mutant KRAS and NRAS. Patients can be selected for treatment based on their mutational profile, eliminating unnecessary treatment of patients without the targets.
Portable Genomics' mission is to pioneer the mobile genomics software space with a consumer-based approach for the visualization and use of genome information in professional and mass-market applications. In the booming field of genomics, there is a need for user-friendly tools to better understand and use genome information in multiple fields from diagnostic and education applications to personalized and preventive medicine solutions.
Poseida Therapeutics, Inc. is currently developing CAR-T and gene therapy products for cancer and orphan diseases. Spinout of Transposagen Biopharmaceuticals early this year, Poseida is also collaborating with J&J’s Janssen to develop allogeneic CAR-T therapies against cancer. Poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. Proprietary tools include piggyBac™ DNA Modification System, NextGEN™ CRISPR, XTN™ TALEN and Footprint-Free™ Gene Editing System, which are clean (synthetic and virus-free) and can be surgically precise. Poseida aims to shuttle the first CAR-T and gene therapy product candidates into Phase I clinical trials in early 2016.
Primordial Genetics Inc. has developed Function Generator™, a novel combinatorial gain-of-function genetic technology designed to enhance productivities of microbes used for the production of proteins (therapeutic proteins, industrial enzymes) and chemicals / fuels / pharmaceuticals. Function Generator™ has been validated in baker's yeast (Saccharomyces cerevisiae) and the laboratory bacterium Escherichia coli.
Renascions is a privately held company focused on clinical stage drug development. Our proprietary technology improves trial outcomes by selecting the right patient cohort for a specific drug.
We are focused on improving drug efficacy in oncology, metabolic disorders, cardiovascular diseases, viral infections, and immunological diseases.
“Targeted therapy stops the bleeding.” This key statement aimed at our customers, drives all innovation activities at Tem®.
Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates (glycans). These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric, and breast, and are exploited by tumor cells to suppress innate immune function, enable tissue invasion and metastasis, resist chemotherapy, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and overcome chemo-resistance.
Origin: San Diego, CA | Leadership: Elisabeth Gardiner, CSO
Discovery and development of small molecule drugs that block inflammatory signaling in the brain. Our goal is provide life changing disease modifying therapeutics for cognitive impairment and brain injury.
Our mission and our passion is to facilitate advances in healthcare and personalized medicine by creating technologies and products that help uncover the biological complexities of disease at the level of each single cell.
Silicon Biosystems’ proprietary technologies offers an unprecedented capability to study rare cells and determine the biological significance of distinct subpopulations of cells within a sample. With this knowledge, our customers are developing new diagnostic and therapeutic strategies to improve patient outcomes and address unmet medical needs.
Silicon Biosystems is a wholly owned and operated subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company. Silicon Biosystems is based in Bologna, Italy.
StemGuard aims to develop therapeutics that target neural stem cells to prevent cognitive decline.
At Stemiotics, Inc. we generate iPSCs from human fibroblasts by using messenger RNA (mRNA) transfection, the fastest and most efficient method yet devised for reprogramming these cells to pluripotency. Since mRNA is rapidly degraded inside cells our reprogramming system is completely “footprint-free.” The mRNA system also eliminates any need to purge or screen for residual traces of vector, as entailed by other popular non-integrating strategies relying on episomal DNA or Sendai virus..
We use only xeno-free reagents at all steps in our pipeline, from fibroblast recovery to reprogramming to stem cell expansion to iPSC freeze-down. We do not use feeder cells, conditioned media or small molecules (with their potential for off-target effects) at any stage in the iPSC production process.
Origin: San Diego, CA | Leadership: Xin Li, CEO. Hiroshi Nakanishi, CSO; John Reiner, VP
Focus: Therapeutics/Wireless Health
Acquisition, development, and commercialization of novel proprietary products targeting cancers and other diseases. Sunvita’s strategic approach utilizes cancer stem cells and cancer immune pathway targets to address the need for new therapies that will have a major impact in the lives of patients.
Commencement date 01/27/2014
Origin: Munich, Germany | Leadership: Robert Hillman
Medical diagnostic systems that provide a comprehensive profile of a patient's coagulation status.
Early stage R&D of bispecific antibodies for the treatment of hematological malignancies and solid tumors
Commencement date 05/21/2012
Universal DX is a biomedicine early-stage company working in the intersection between metabolomics and bioinformatics, with the mission to develop and commercialize blood tests for the early detection of cancer
Vanguard Therapeutics, Inc.
Vanguard is developing an oral cell adhesion blocking agent to be used for long-term prophylactic therapy of patients with sickle cell disease.
Vedanta was founded by PureTech Ventures and a team of world renowned experts in immunology and microbiology. Vedanta is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta’s proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.
Origin: San Diego, CA | Leadership: Boris Markosian, Founder and CEO; Brandon Dolan, Director of scientific research; Daniel Dempsey, Director of operations; Thomas Ichim, CSO
Vaxenta focuses on the development and commercialization of safe, natural, and effective cancer therapies.
Origin: San Diego, CA | Leadership: Troy Wilson, President & CEO
Discovery and development of small molecule drugs that target signal transduction networks for the treatment of cancer and other diseases.
Wibi+Works, LLC., located in the Janssen Labs incubator space in San Diego, is focused on the development and commercialization of new therapies for inflammatory diseases.
Wibi+Works, LLC. has assembled a team to quickly advance a unique patent-pending technology for safe and effective cell therapies that target hard to treat inflammatory diseases.
Wibi+Works, LLC., a privately held, emerging biotechnical company, was founded in 2010. In October 2010 the company received a Phase Zero from the State of Louisiana. In December 2011 the company submitted a SHIFT-SBIR Phase I award (NIH) for advancing the first stem cell-based therapy in Rheumatoid Arthritis (RA). It was awarded in September 2012.
XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.
Yolia Health is an ophthalmic bio-med company that helps vision correction practitioners preserve, restore and enhance vision. The company has developed an ophthalmic corrective procedure that promises to revolutionize the vision-aid industry, by offering a unique, non-invasive method for correcting low refractive errors and presbyopia, an eye condition that affects people over the age of forty. In simpler terms, their product is a semi-permanent, contact lenses, normally worn only at night, to improve vision through the reshaping of the cornea. Fusion is a strategic investor in the firm and provides a Strategic CFO role in accelerating the growth of the company.